Lite Strategy (LITS) Total Non-Current Liabilities (2011 - 2026)
Lite Strategy (LITS) posted quarterly Total Non-Current Liabilities of $952000.0 for Q1 2026, up 126.0% year-over-year from $421245.0 in Q1 2025, and down 12.42% quarter-over-quarter from $1.1 million in Q4 2025.
Lite Strategy (LITS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Lite Strategy's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $952000.0 for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 126.0% year-over-year to $952000.0; the TTM figure through Mar 2026 stood at $952000.0 (up 126.0% YoY), while the FY2025 annual figure was $1.4 million, down 83.79% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $952000.0, down from $1.1 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $125.8 million in Q3 2022, with the low at -$3.7 million in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $14.2 million (2023), against an average of $42.6 million.
- The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities slumped 118.47% in 2024, then jumped 141.6% in 2025.
- Lite Strategy's Total Non-Current Liabilities stood at $99.2 million in 2022, then plunged by 85.74% to $14.2 million in 2023, then plunged by 118.47% to -$2.6 million in 2024, then jumped by 141.6% to $1.1 million in 2025, then dropped by 12.42% to $952000.0 in 2026.
- Business Quant data shows LITS's Total Non-Current Liabilities at $952000.0 in Q1 2026, $1.1 million in Q4 2025, and -$932000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 9.32 Bn |
| 10 | Lite Strategy | 36.96 Mn | 29.42 Mn | - | -1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 952,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | -932,000.00 |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | -3.66 Mn |
| Dec 31, 2024 | -2.61 Mn |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | 8.36 Mn |
| Mar 31, 2024 | 20.23 Mn |
| Dec 31, 2023 | 14.15 Mn |
| Sep 30, 2023 | 17.89 Mn |
| Jun 30, 2023 | 96.19 Mn |
| Mar 31, 2023 | 99.83 Mn |
| Dec 31, 2022 | 99.23 Mn |
| Sep 30, 2022 | 125.78 Mn |
| Jun 30, 2022 | 123.82 Mn |
| Mar 31, 2022 | 125.09 Mn |
| Dec 31, 2021 | 121.82 Mn |
| Sep 30, 2021 | 122.28 Mn |
| Jun 30, 2021 | 102.28 Mn |